Evidence-based staging system for malignant melanoma: Is new necessarily better?

Lancet

Volumn 364, Issue 9432, 2004, Pages 395-396

  Baron, Jens M ^a   Abuzahra, Faris ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EVIDENCE BASED MEDICINE; HUMAN; MELANOMA; METASTASIS; NOTE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT INDICATION;

EID: 3843137524     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16780-9     Document Type: Note

References (8)

1. Baron JM, Heise R, Merk HF, Abuzahra F. Current and future directions in the treatment of metastatic malignant melanoma. Curr Med Chem Anti-Canc Agents. 3:2003;393-398
2. Kim CJ, Reintgen DS, Balch CM. The new melanoma staging system. Cancer Control. 9:2002;9-15
3. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 54:2004;131-149
4. Roberts DL, Anstey AV, Barlow RJ, et al. UK guidelines for the management of cutaneous melanoma. Br J Dermatol. 146:2002;7-17
5. Kaufmann R, Tilgen W, Garbe C. Malignant melanoma. Hautarzt. 48:(suppl 1):1998;S30-38
6. Garbe C, Leiter U, Ellwanger U, et al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer. 97:2003;1737-1745
7. Nambiar S, Mirmohammadsadegh A, Bar A, et al. Applications of array technology: melanoma research and diagnosis. Expert Rev Mol Diagn. 4:2004;549-557
8. Abuzahra F, Heise R, Joussen S, et al. Adjuvant IFN( therapy stimulates transporter proteins associated with antigen processing and proteasome activator 28 in patients with malignant melanoma. Lancet Oncol. 5:2004;250